J R Zanchetta
Overview
Explore the profile of J R Zanchetta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
2835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bilezikian J, Hattersley G, Fitzpatrick L, Harris A, Shevroja E, Banks K, et al.
Osteoporos Int
. 2017 Nov;
29(2):323-328.
PMID: 29167971
Introduction: Subcutaneous abaloparatide (abaloparatide-SC) increases total hip and lumbar spine bone mineral density and reduces vertebral and non-vertebral fractures. In this study, we analyzed the extent to which abaloparatide-SC improves...
2.
Zanchetta M, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta J
Osteoporos Int
. 2017 Oct;
29(1):41-47.
PMID: 28975362
Introduction: Denosumab (DMAb) is a soluble inhibitor of the receptor activator of nuclear factor-kappaB ligand (RANKL) and, therefore, does not incorporate into the bone matrix. Consistently, DMAb discontinuation is associated...
3.
McClung M, Lippuner K, Brandi M, Zanchetta J, Bone H, Chapurlat R, et al.
Osteoporos Int
. 2017 Jul;
28(10):2967-2973.
PMID: 28748386
Introduction: TBS, a gray-level texture index determined from lumbar spine DXA scans, correlates with bone microarchitecture and enhances assessment of vertebral fracture risk independently of BMD. In the FREEDOM study,...
4.
Mana D, Zanchetta M, Zanchetta J
Osteoporos Int
. 2016 Dec;
28(4):1491-1494.
PMID: 27966106
Teriparatide is a drug for the treatment of osteoporosis which is licensed for use for up to 24 months. There is little experience with retreatment. The aim of this study...
5.
Zanchetta M, Scioscia M, Zanchetta J
Osteoporos Int
. 2016 Apr;
27(9):2873-2877.
PMID: 27068223
We present the case of a 28-year-old female Rett syndrome patient with low bone mass and a recent fracture who was successfully treated with teriparatide. Bone mineral density and microarchitecture...
6.
McClung M, Zanchetta J, Racewicz A, Roux C, Benhamou C, Man Z, et al.
Osteoporos Int
. 2012 Jul;
24(1):293-9.
PMID: 22752050
Unlabelled: This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the treatment of postmenopausal osteoporosis. This...
7.
Negri A, Del Valle E, Zanchetta M, Nobaru M, Silveira F, Puddu M, et al.
Osteoporos Int
. 2012 Jan;
23(10):2543-50.
PMID: 22234812
Unlabelled: Hemodialyzed patients have decreased bone strength not completely characterized. We evaluated bone microarchitecture in hemodialysis patients and compared it to that of subjects without renal disease by high-resolution peripheral...
8.
Zanchetta J, Cortes E, Pallotta M, Dominguez J
Medicina (B Aires)
. 2011 Dec;
40(6 Pt 1):643-9.
PMID: 22167695
A total of 82 episodes of diabetic ketoacidosis were analysed in 70 adult patients. Population characteristics can be seen in Table 1. It was possible to determine the causes of...
9.
Hadji P, Zanchetta J, Russo L, Recknor C, Saag K, McKiernan F, et al.
Osteoporos Int
. 2011 Dec;
23(8):2141-50.
PMID: 22159672
Unlabelled: The effect of teriparatide and risedronate on back pain was tested, and there was no difference in the proportion of patients experiencing a reduction in back pain between groups...
10.
Bogado C, Boailchuk J, Zanchetta M, Massari F, Zanchetta J
Drugs Today (Barc)
. 2011 Aug;
47(8):605-13.
PMID: 21850283
Denosumab is a fully human monoclonal antibody that inhibits the formation, function and survival of osteoclasts, preventing the interaction of tumor necrosis factor ligand superfamily member 11 (receptor activator of...